scispace - formally typeset
A

Arthur R. Menezes

Researcher at University of Queensland

Publications -  23
Citations -  1222

Arthur R. Menezes is an academic researcher from University of Queensland. The author has contributed to research in topics: Stroke & Referral. The author has an hindex of 17, co-authored 23 publications receiving 1052 citations. Previous affiliations of Arthur R. Menezes include Pennington Biomedical Research Center.

Papers
More filters
Journal ArticleDOI

L-Carnitine in the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis

TL;DR: A systematic review and meta-analysis of 13 controlled trials found that L-carnitine is associated with a 27% reduction in all-cause mortality, a 65% Reduction in VAs, and a 40% reductionIn anginal symptoms in patients experiencing an acute myocardial infarction.
Journal ArticleDOI

Atrial Fibrillation in the 21st Century: A Current Understanding of Risk Factors and Primary Prevention Strategies

TL;DR: The widely established risk factors for AF are discussed and newer risk factors currently being investigated that may have implications in the primary prevention of AF are explored.
Journal ArticleDOI

Impact of Cardiac Rehabilitation and Exercise Training on Psychological Risk Factors and Subsequent Prognosis in Patients With Cardiovascular Disease.

TL;DR: Emerging data from cardiac rehabilitation settings and CR exercise training programs have demonstrated the value of comprehensive CRET to improve psychological functioning and reduce all-cause mortality.
Journal ArticleDOI

Cardiac rehabilitation in the United States

TL;DR: Some of the many benefits of CR are discussed, some of the risk factors for CHD in the US, and factors that affect referral and participation in these programs are discussed.
Journal ArticleDOI

Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol).

TL;DR: In this paper, a systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolols, nebivolol or carvedilol to evaluate the effects of carvedilolin compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of acute myocardial infarction (AMI) and heart failure (HF) settings.